In the phase III APHINITY trial (NCT01358877), adding pertuzumab to trastuzumab and chemotherapy improved the rates of invasive disease-free survival (iDFS) among patients with HER2+ early breast cancer (EBC) [56]. This evidence concerns the gene ERBB2 and breast carcinoma.